Abstract
ISARIC (International Severe Acute Respiratory and emerging Infections Consortium) partnerships and outbreak preparedness initiatives enabled the rapid launch of standardised clinical data collection on COVID-19 in Jan 2020. Extensive global uptake of this resource has resulted in a large, standardised collection of comprehensive clinical data from hundreds of sites across dozens of countries. Data are analysed regularly and reported publicly to inform patient care and public health response. This report, our 15th report, is a part of a series and includes the results of data analysis for data captured before 26 May 2021. The report marks a significant milestone – the submission of clinical data from over half a million individuals hospitalised with COVID-19. We thank all of the data contributors for their ongoing support.
Data have been entered for 516,689 individuals from 788 partner institutions and networks, covering more than 1600 sites across 61 countries. This is a significant increase in data volumes and contributing countries since our most recent report dated 08 April 2021.
The comprehensive analyses detailed in this report includes hospitalised individuals of all ages:
for whom data collection occurred between 30 January 2020 and up to and including 25 May 2021; AND
who have laboratory-confirmed SARS-COV-2 infection or clinically diagnosed COVID-19.
For the 442,643 cases who meet eligibility criteria for this report, selected findings include:
median age of 60 years, with an approximately equal (50/50) male:female sex distribution
one third of the cohort are at least 70 years of age, whereas 3% are 0-19 years of age
the most common symptom combination in this hospitalised cohort is shortness of breath, cough, and history of fever, which has remained constant over time
the five most common symptoms at admission were shortness of breath, cough, history of fever, fatigue/malaise, and altered consciousness/confusion, which is unchanged from the previous reports
age-associated differences in symptoms are evident, including the frequency of altered consciousness increasing with age, and fever, respiratory and constitutional symptoms being present mostly in those 40 years and above
16% of patients with relevant data available were admitted at some point during their illness into an intensive care unit (ICU), which is slightly lower than previously reported (19%)
antibiotic use remains very high (61%), although it is lower than previously reported (80%), in those for whom relevant data are available (288,125); in ICU/HDU patients with data available (36,073), 92% received antibiotics
use of corticosteroids was reported for 25% of patients of all types for whom data were available (288,125); in ICU/HDU patients with data available (36,021), 62% received corticosteroids
outcomes are known for 411,368 patients and the overall estimated case fatality ratio (CFR) is 25% (95%CI 24.8-25), rising to 38% (95%CI 37.5-38.3) for patients who were admitted to ICU/HDU, demonstrating worse outcomes in those with the most severe disease
To access previous versions of ISARIC COVID-19 Clinical Data Report please use the link below: https://isaric.org/research/covid-19-clinical-research-resources/evidence-reports/
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
Funding Statement
This work is supported by grants including: the National Institute for Health Research (NIHR award CO-CIN-01); the Medical Research Council (MRC grant MC_PC_19059); the NIHR Health Protection Research Unit in Emerging and Zoonotic Infections at the University of Liverpool in partnership with Public Health England (PHE), Liverpool School of Tropical Medicine and the University of Oxford (NIHR award 200907); UK Foreign, Commonwealth and Development Office; Wellcome [215091/Z/18/Z]; the Bill & Melinda Gates Foundation [OPP1209135]; and Liverpool Experimental Cancer Medicine Centre (infrastructure support reference C18616/A25153). Contents of the publication are those of the authors and not necessarily reflect those of the funders. Additional funding support can be viewed on the final page of the report.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee approval was given by the WHO Ethics Review Committee (RPC571 and RPC572, 25 April 2013). Institutional approval was additionally obtained by participating sites including the South Central - Oxford C Research Ethics Committee in England (Ref 13/SC/0149), the Scotland A Research Ethics Committee (Ref 20/SS/0028) for the UK, which represents the majority of the data. Other institutional and national approvals are in place as per local requirements.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* group members, participating institutions and funders are listed at end of report and at https://isaric.org/research/covid-19-clinical-research-resources/covid-19-data-management-hosting/covid-19-clinical-data-contributors-list/
A global federation of clinical research networks, providing a proficient, coordinated, and agile research response to outbreak-prone infectious diseases
This is an updated version of ISARIC COVID-19 Clinical Data Report: 14 July 2021 Submitted 6SEP21
Data Availability
We welcome applications for access to data on the COVID-19 Data Sharing Platform via the Data Access Committee (www.iddo.org/covid-19).
